论文部分内容阅读
《亚洲医学新闻》第4卷第3期(1982年)报道纽瓦克消息:新泽西州内科和牙科学院(CMDNJ)正在对一种眼药水进行试验,总有一天,一种治疗用的眼药水可预防糖尿病病人的白内障。上述眼药水的作用成分是一种称作Sorbi-nil(Pfizer)的物质,是一种醛糖还原酶抑制剂。迄今,用大白鼠的实验证明,这种眼药水可预防或至少延缓未成熟的糖尿病白内障的形成。临床试验即将进行。美国国立眼科研究所的主任木下(JinKinoshita)说,如果实验结果也可适用于人类,对于用手术治疗糖尿病性白内障则将是一项突破。
NEW YORK (Reuters) - Newark, NJ (CMDNJ) is experimenting with an eye drop and one day, a therapeutic eye drop Can prevent cataracts in diabetic patients. The ophthalmic solution is a substance called Sorbi-nil (Pfizer) and is an aldose reductase inhibitor. To date, experiments with rats have demonstrated that such eye drops can prevent or at least delay the development of immature diabetic cataracts. Clinical trials are coming soon. Jin Kinoshita, director of the National Eye Institute, said that if the results of the experiment are also applicable to humans, it would be a breakthrough for the surgical treatment of diabetic cataracts.